Highlights the need for further clinical studies to determine optimal antithrombotic management and the utility of cerebral embolic protection in patients undergoing transcatheter heart valve interventions.
Stroke prevention strategies remain undefined after transcatheter valve interventions; leaves open questions for dedicated randomized trials.
Stroke in patients with valvular heart disease undergoing transcatheter intervention is relatively rare but associated with significant morbidity and mortality. Risks vary according to the underlying valve disease and proposed procedure. While major improvements have been made in developing and understanding the technical factors associated with intra- and peri-procedural stroke, uncertainty exists regarding the optimal antithrombotic management strategy after transcatheter heart valve intervention and the utility of routine cerebral embolic protection. Further clinical studies are warranted to minimise these complications.
No takes yet. Share an insight, caveat, or question.
Giustino et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: